Affymax folds after drug withdrawal

Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anaemia drug Omontys (peginesatide).

An investigation in conjunction with its marketing partner Takeda found no quality or manufacturing issues with Omontys. However, it also failed to identify any specific root cause for the allergic reactions, so the companies were left with no option but to withdraw the product. Takeda has broken off its marketing agreement with Affymax, effective from 10 September and, subject to shareholder approval, the company will be liquidated .

Omontys is a PEGylated peptide drug used to treat anaemia caused by chronic kidney disease.

Related Content

Eye drops show promise treating cataracts and even reversing damage

6 November 2015 Research

news image

Sterol compound can ‘dissolve’ mis-folded proteins to help clear the lens offering hope to 100 million in developing worl...

Folding rules used to build unnatural proteins

27 October 2014 Research

news image

Understanding protein folding and stability leads to new proteins with hopes of creating structures that can perform novel ch...

Most Commented

Chlorinated compounds form in tea and coffee

24 November 2015 Research

news image

Treated water reacts with organics to form disinfection byproducts

Brazilian mine disaster releases dangerous metals

21 November 2015 News and Analysis

news image

Irreversible negative human health and environmental effects could result from Brazilian mine’s dam collapse